167 related articles for article (PubMed ID: 30769243)
1. Synthesis, docking and antibacterial studies of more potent amine and hydrazone rifamycin congeners than rifampicin.
Pyta K; Janas A; Szukowska M; Pecyna P; Jaworska M; Gajecka M; Bartl F; Przybylski P
Eur J Med Chem; 2019 Apr; 167():96-104. PubMed ID: 30769243
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationship studies of new rifamycins containing l-amino acid esters as inhibitors of bacterial RNA polymerases.
Czerwonka D; Domagalska J; Pyta K; Kubicka MM; Pecyna P; Gajecka M; Przybylski P
Eur J Med Chem; 2016 Jun; 116():216-221. PubMed ID: 27061985
[TBL] [Abstract][Full Text] [Related]
3. Novel C-3-(N-alkyl-aryl)-aminomethyl rifamycin SV derivatives exhibit activity against rifampicin-resistant Mycobacterium tuberculosis RpoB
Zloh M; Gupta M; Parish T; Brucoli F
Eur J Med Chem; 2021 Dec; 225():113734. PubMed ID: 34418786
[TBL] [Abstract][Full Text] [Related]
4. Specific Interactions between Rifamycin Antibiotics and Water Influencing Ability To Overcome Natural Cell Barriers and the Range of Antibacterial Potency.
Pyta K; Janas A; Skrzypczak N; Schilf W; Wicher B; Gdaniec M; Bartl F; Przybylski P
ACS Infect Dis; 2019 Oct; 5(10):1754-1763. PubMed ID: 31461259
[TBL] [Abstract][Full Text] [Related]
5. Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins.
Li J; Ma Z; Chapo K; Yan D; Lynch AS; Ding CZ
Bioorg Med Chem Lett; 2007 Oct; 17(20):5510-3. PubMed ID: 17826091
[TBL] [Abstract][Full Text] [Related]
6. Structure and evaluation of antibacterial and antitubercular properties of new basic and heterocyclic 3-formylrifamycin SV derivatives obtained via 'click chemistry' approach.
Pyta K; Klich K; Domagalska J; Przybylski P
Eur J Med Chem; 2014 Sep; 84():651-76. PubMed ID: 25063947
[TBL] [Abstract][Full Text] [Related]
7. The antibacterial activity of a new 3-azinomethyl-rifamycin.
Strippoli V; Bruzzese T; Galli R; Simonetti N; Tronci N
Farmaco Sci; 1988; 43(7-8):619-25. PubMed ID: 3147199
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationships of novel substituted 8-amino, 8-thio, and 1,8-pyrazole congeners of antitubercular rifamycin S and rifampin.
Jin Y; Gill SK; Kirchhoff PD; Wan B; Franzblau SG; Garcia GA; Showalter HD
Bioorg Med Chem Lett; 2011 Oct; 21(20):6094-9. PubMed ID: 21903392
[TBL] [Abstract][Full Text] [Related]
9. Rifamycin Derivatives Are Effective Against Staphylococcal Biofilms In Vitro and Elutable From PMMA.
Sanchez CJ; Shiels SM; Tennent DJ; Hardy SK; Murray CK; Wenke JC
Clin Orthop Relat Res; 2015 Sep; 473(9):2874-84. PubMed ID: 25896136
[TBL] [Abstract][Full Text] [Related]
10. Rifamycin inhibition of WT and Rif-resistant Mycobacterium tuberculosis and Escherichia coli RNA polymerases in vitro.
Gill SK; Garcia GA
Tuberculosis (Edinb); 2011 Sep; 91(5):361-9. PubMed ID: 21704562
[TBL] [Abstract][Full Text] [Related]
11. The Enzymes of the Rifamycin Antibiotic Resistome.
Surette MD; Spanogiannopoulos P; Wright GD
Acc Chem Res; 2021 May; 54(9):2065-2075. PubMed ID: 33877820
[TBL] [Abstract][Full Text] [Related]
12. Rox, a Rifamycin Resistance Enzyme with an Unprecedented Mechanism of Action.
Koteva K; Cox G; Kelso JK; Surette MD; Zubyk HL; Ejim L; Stogios P; Savchenko A; Sørensen D; Wright GD
Cell Chem Biol; 2018 Apr; 25(4):403-412.e5. PubMed ID: 29398560
[TBL] [Abstract][Full Text] [Related]
13. Antibacterial activity of rifamycins for M. smegmatis with comparison of oxidation and binding to tear lipocalin.
Staudinger T; Redl B; Glasgow BJ
Biochim Biophys Acta; 2014 Apr; 1844(4):750-8. PubMed ID: 24530503
[TBL] [Abstract][Full Text] [Related]
14. Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections.
Ma Z; Lynch AS
J Med Chem; 2016 Jul; 59(14):6645-57. PubMed ID: 27336583
[TBL] [Abstract][Full Text] [Related]
15. The effect of complexation of 3-formylrifamycin SV macrocyclic ether derivatives with metal cations and small nitrogen-containing organic molecules on antibacterial activity against S. aureus and S. epidermidis.
Przybylski P; Pyta K; Czerwonka D; Kubicka MM; Gajecka M
Bioorg Med Chem Lett; 2015 Sep; 25(18):3903-9. PubMed ID: 26254943
[TBL] [Abstract][Full Text] [Related]
16. New C25 carbamate rifamycin derivatives are resistant to inactivation by ADP-ribosyl transferases.
Combrink KD; Denton DA; Harran S; Ma Z; Chapo K; Yan D; Bonventre E; Roche ED; Doyle TB; Robertson GT; Lynch AS
Bioorg Med Chem Lett; 2007 Jan; 17(2):522-6. PubMed ID: 17070048
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, SAR and molecular docking studies of benzo[d]thiazole-hydrazones as potential antibacterial and antifungal agents.
Zha GF; Leng J; Darshini N; Shubhavathi T; Vivek HK; Asiri AM; Marwani HM; Rakesh KP; Mallesha N; Qin HL
Bioorg Med Chem Lett; 2017 Jul; 27(14):3148-3155. PubMed ID: 28539243
[TBL] [Abstract][Full Text] [Related]
18. HelR is a helicase-like protein that protects RNA polymerase from rifamycin antibiotics.
Surette MD; Waglechner N; Koteva K; Wright GD
Mol Cell; 2022 Sep; 82(17):3151-3165.e9. PubMed ID: 35907401
[TBL] [Abstract][Full Text] [Related]
19. Regioselective long-range proton transfer in new rifamycin antibiotics: a process in which crown ethers act as stronger Brønsted bases than amines.
Pyta K; Przybylski P; Bartl F
Chemphyschem; 2015 Apr; 16(5):938-42. PubMed ID: 25639734
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus.
Murphy CK; Mullin S; Osburne MS; van Duzer J; Siedlecki J; Yu X; Kerstein K; Cynamon M; Rothstein DM
Antimicrob Agents Chemother; 2006 Mar; 50(3):827-34. PubMed ID: 16495239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
